{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:20:33Z","timestamp":1788618033007,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.clml.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T20:32:38Z","timestamp":1528835558000},"page":"e351-e362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Avi","family":"Leader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Benyamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronya","family":"Calvarysky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Amitai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Yarchovsky-Dolberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giora","family":"Sharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opher","family":"Caspi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"De Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.06.007_bib1","first-page":"1497","article-title":"A\u00a0minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.clml.2018.06.007_bib2","first-page":"112","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.007_bib4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.007_bib5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.007_bib6","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood.V120.21.163.163","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the Prospective, Multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib9","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib10","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2018.06.007_bib12","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia","volume":"34","author":"Winn","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.06.007_bib14","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A\u00a0new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2018.06.007_bib16","doi-asserted-by":"crossref","first-page":"371.e3","DOI":"10.1016\/j.clml.2016.02.040","article-title":"Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib","volume":"16","author":"Unnikrishnan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.06.007_bib17","first-page":"13","article-title":"PCN48. Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short- and long-term negative impacts on health care resource utilization and costs","author":"Guerin","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2018.06.007_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","article-title":"Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study","volume":"107","author":"Efficace","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2018.06.007_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000345722","article-title":"Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort","volume":"130","author":"de Almeida","year":"2013","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2018.06.007_bib20","first-page":"116","article-title":"Disease knowledge in chronic myeloid leukemia (CML) patients as a predictor of compliance to treatment","author":"Johnson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib21","first-page":"116","article-title":"A\u00a0global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML)","author":"Guilhot","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib22","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1200\/jco.2006.24.18_suppl.6038","article-title":"Compliance and persistency with imatinib","volume":"24","author":"Feng","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hon.2005","article-title":"Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC","volume":"30","author":"Koren-Michowitz","year":"2012","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib24","first-page":"114","article-title":"Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients","author":"Bazeos","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib25","unstructured":"Abraham I, Lee C, MacDonald K, et\u00a0al. No margin for non-adherence: novel application of Kaplan-Meier methods to model the efficacy of adherence to imatinib treatment by patients with chronic myeloid leukemia (the ADAGIO study). Paper presented at: European Society for Patient Adherence, Compliance and Persistence; Ghent, Belgium; October 25-27,\u00a02012."},{"key":"10.1016\/j.clml.2018.06.007_bib26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","article-title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges","volume":"99","author":"Noens","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.06.007_bib27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jac\/dki066","article-title":"Patient adherence to prescribed antimicrobial drug dosing regimens","volume":"55","author":"Vrijens","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clml.2018.06.007_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.007_bib29","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2016-07-726893","article-title":"Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children\u2019s Oncology Group study","volume":"129","author":"Landier","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00019053-200725040-00002","article-title":"Measuring patient-reported outcomes in solid organ transplant recipients: an overview of instruments developed to date","volume":"25","author":"Cleemput","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2018.06.007_bib31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clml.2018.06.007_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.06.007_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.leukres.2012.01.021","article-title":"Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia","volume":"36","author":"Gater","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.06.007_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00277-011-1359-0","article-title":"Good adherence to imatinib therapy among patients with chronic myeloid leukemia\u2014a single-center observational study","volume":"91","author":"Jonsson","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.06.007_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.1174","article-title":"Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia","volume":"33","author":"Daouphars","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clml.2018.06.007_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.critrevonc.2015.08.025","article-title":"To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients","volume":"97","author":"Hall","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2018.06.007_bib37","series-title":"Adherence to Long-Term Therapies: Evidence for Action","author":"World Health Organization","year":"2003"},{"key":"10.1016\/j.clml.2018.06.007_bib38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12032-017-0958-6","article-title":"Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors","volume":"34","author":"Rychter","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2018.06.007_bib41","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","article-title":"Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients","volume":"39","author":"Breccia","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.06.007_bib42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2018.06.007_bib43","first-page":"114","article-title":"Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia","author":"St Charles","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib44","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2018.06.007_bib45","first-page":"1006","article-title":"Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment","volume":"20","author":"Trivedi","year":"2014","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2018.06.007_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.06.026","article-title":"The effect of adherence-enhancing interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): a quasi-experimental pre-post intervention multicenter pilot study","author":"Leader","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.06.007_bib47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.007_bib48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.qai.0000246034.86135.89","article-title":"Use of electronic monitoring induces a 40-day intervention effect in HIV patients","volume":"43","author":"Deschamps","year":"2006","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clml.2018.06.007_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","article-title":"Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories","volume":"52","author":"Blaschke","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clml.2018.06.007_bib50","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1600-6143.2007.02127.x","article-title":"Diagnostic accuracy of measurement methods to assess non-adherence to immunosuppressive drugs in kidney transplant recipients","volume":"8","author":"Sch\u00e4fer-Keller","year":"2008","journal-title":"Am J Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018304233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018304233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:47Z","timestamp":1761870647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018304233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S2152265018304233"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}